Hims & Hers Health (HIMS) to Release Quarterly Earnings on Monday

Hims & Hers Health (NYSE:HIMS - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data after the market closes on Monday, May 5th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $535.21 million for the quarter. Hims & Hers Health has set its Q1 2025 guidance at EPS and its FY 2025 guidance at EPS.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Hims & Hers Health Trading Down 0.1 %

Shares of NYSE HIMS opened at $28.10 on Monday. The firm has a market cap of $6.24 billion, a PE ratio of 63.87 and a beta of 1.65. Hims & Hers Health has a 1-year low of $11.20 and a 1-year high of $72.98. The company has a fifty day moving average price of $34.24 and a 200 day moving average price of $31.08.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total value of $7,465,960.29. Following the transaction, the chief executive officer now directly owns 97,687 shares of the company's stock, valued at $5,692,221.49. This represents a 56.74 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Soleil Boughton sold 4,152 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the transaction, the insider now directly owns 157,345 shares in the company, valued at approximately $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 712,998 shares of company stock valued at $27,992,450. 17.71% of the stock is owned by insiders.

Analyst Ratings Changes

HIMS has been the subject of a number of research analyst reports. Piper Sandler upped their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 25th. Morgan Stanley downgraded shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and increased their price objective for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. BTIG Research assumed coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They set a "buy" rating and a $35.00 price objective for the company. Leerink Partners increased their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Finally, Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a research note on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and a consensus target price of $38.08.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.